A phase II study evaluating the safety and efficacy of sunitinib maleate in combination with weekly paclitaxel followed by doxorubicin and daily oral cyclophosphamide plus G-CSF [granulocyte colony-stimulating factor] as neoadjuvant chemotherapy for locally advanced or inflammatory breast cancer.

Trial Profile

A phase II study evaluating the safety and efficacy of sunitinib maleate in combination with weekly paclitaxel followed by doxorubicin and daily oral cyclophosphamide plus G-CSF [granulocyte colony-stimulating factor] as neoadjuvant chemotherapy for locally advanced or inflammatory breast cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Cyclophosphamide; Doxorubicin; Filgrastim; Paclitaxel; Sunitinib
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 28 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top